Other
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five
Biogen Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five increased by 8.7% to $455.90M in Q1 2026 compared to the prior quarter. Over 3 years (FY 2020 to FY 2025), Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five shows a downward trend with a -16.5% CAGR.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ1 2016
Last reportedQ1 2026
How to read this metric
Changes in this bucket reflect shifts in the company's duration management and medium-term reinvestment strategy.
Detailed definition
This represents the amortized cost of debt securities in the available-for-sale portfolio that have maturity dates betwe...
Peer comparison
Standard maturity bucket reporting for insurance investment portfolios.
Metric ID:
other_available_for_sale_securities_debt_maturities_afte_2b276aHistorical Data
11 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $870.90M | $925.50M | $870.20M | $982.90M | $1.09B | $848.30M | $703.70M | $965.80M | $1.20B | $419.30M | $455.90M |
| QoQ Change | — | +6.3% | -6.0% | +13.0% | +10.8% | -22.1% | -17.0% | +37.2% | +24.5% | -65.1% | +8.7% |
| YoY Change | — | — | — | — | +25.1% | -8.3% | -19.1% | -1.7% | +10.4% | — | — |
Range$419.30M – $1.20B
CAGR-22.8%
Avg YoY Growth+1.3%
Median YoY Growth-1.7%
Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five at Other Companies
Frequently Asked Questions
- What is Biogen's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five?
- Biogen (BIIB) reported debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five of $455.90M in Q1 2026.
- What is the long-term trend for Biogen's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five?
- Over 3 years (2020 to 2025), Biogen's debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five has grown at a -16.5% compound annual growth rate (CAGR), from $721.30M to $419.30M.
- What does debt securities, available-for-sale, amortized cost, maturity, allocated and single maturity date, after year one through five mean?
- The book value of debt investments maturing between one and five years from now.